Joseph Lister is remembered as the man who made surgery safe. His introduction of antiseptic technique in the 1860s is one of the most celebrated moments in the history of medicine, and rightly so. Lister saved countless lives, and the principles he established — that surgical environments must be kept free of microbial contamination — underpin everything we do in operating theatres today.
But there is a version of Lister's story that you probably weren't taught in school. And once you understand it, you may find yourself asking some uncomfortable questions about the direction medicine has taken since.
The Facts: What Lister Actually Did
Let's start with the historical record, because it's important to get this right before we go any further.
Joseph Lister (1827–1912) was a British surgeon who, in 1865, began applying carbolic acid — a phenol compound derived from coal tar — to surgical wounds and instruments at Glasgow Royal Infirmary. His method was inspired by Louis Pasteur's germ theory, which proposed that microorganisms were responsible for fermentation and putrefaction. Lister theorised that the same microorganisms might be responsible for post-surgical infection, and that killing them with a chemical antiseptic could prevent it. His results were dramatic: post-operative mortality in his wards fell from approximately 45% to under 15%, and eventually lower still. He published his findings in The Lancet in 1867.
That is the standard account. And it is accurate. Lister was a genuine genius, a meticulous scientist, and a deeply compassionate physician who was motivated entirely by a desire to stop his patients dying on the operating table.
So where does the buried lesson come in? It comes from looking not just at what Lister did, but at where he looked for inspiration.
Lister Was Inspired by Nature — Not by a Laboratory
Carbolic acid — phenol — is not a synthetic compound invented in a pharmaceutical factory. It occurs naturally in coal tar, a byproduct of coal combustion, and has been found in trace amounts in various plant sources. But more importantly, the concept behind Lister's work was rooted in observation of natural processes.
Lister drew on Pasteur's observations of fermentation and decay — natural microbial processes — to understand infection. The carbolic acid he used to treat sewage in Carlisle before he applied it to wounds was itself a product of processing organic material. And Lister was deeply interested in the body's own healing processes, repeatedly emphasising in his writings that antiseptic technique was designed to support the body's natural repair mechanisms by removing the microbial obstacle — not to replace them with chemical intervention.
"The thing I am aiming at," Lister wrote, "is to avoid any interference with the wonderful natural processes of healing." This is not the language of someone who believed chemistry should override biology. It is the language of someone who believed the body knew how to heal itself if you got the pathogens out of the way.
What Modern Hospital Antiseptics Have Become
Here is where the story gets complicated — and where the lesson Lister taught has arguably been distorted.
Lister used carbolic acid as a targeted intervention to prevent infection. His approach was based on understanding a specific mechanism — microbial contamination of wounds — and addressing it precisely. What emerged over the following century was something rather different: a generalised chemical saturation of hospital environments that some researchers now worry may be creating as many problems as it solves.
A 2019 study examining antibiotic resistance in hospital environments found that certain quaternary ammonium compounds — the active ingredients in many modern hospital disinfectants — may be contributing to cross-resistance, where bacteria that develop tolerance to these chemical agents also show reduced susceptibility to some antibiotics. The study's authors called for further research into whether our current chemical-heavy approach to hospital hygiene is inadvertently worsening the AMR crisis.
Integrative practitioners whom I have spoken with about this research are not surprised. "There is a pattern in mainstream medicine," one experienced naturopath told me, "of taking a good idea and pushing it far beyond what the evidence actually supports, often because there is commercial incentive to do so. Lister had a good idea — kill the pathogens. That doesn't necessarily mean that flooding every surface with toxic chemical cocktails is the logical endpoint of that idea."
The Pharmaceutical Industry's Role
It would be naïve to discuss the development of modern hospital disinfectants and antiseptics without acknowledging the commercial context in which that development happened. The pharmaceutical and chemical industries have enormous financial stakes in the hospital supply chain. The market for hospital disinfectants globally is worth over $6 billion annually and growing.
This does not mean that modern disinfectants don't work. They do. But it does mean that the incentive structure around hospital hygiene is not neutral. When profit-driven companies are the primary source of both the products and the research supporting those products, it is reasonable to ask whether alternatives — including plant-derived antimicrobial agents — have received a fair hearing.
Lister himself, it is worth noting, eventually moved away from carbolic acid as new antiseptic approaches were developed. He was not ideologically committed to any particular chemical — he was committed to the outcome: preventing infection. The question we should be asking, in Lister's spirit, is whether that outcome is best achieved by the products currently dominating clinical practice, or whether there are other approaches worth investigating.
Plant-Based Antimicrobials: The Heirs to Lister's Work?
This is where the conversation becomes genuinely exciting for those of us working in integrative health. Over the past two decades, a substantial body of research — much of it from universities in Europe, Asia, and increasingly Australasia — has been investigating the antimicrobial properties of plant-derived compounds.
Tea tree oil (Melaleuca alternifolia), for instance, has demonstrated significant antimicrobial activity in laboratory conditions, including against some antibiotic-resistant strains of bacteria. Thymol, a compound derived from thyme, is already used as an active ingredient in some commercially available antiseptics. Compounds in manuka honey have been used in wound care for decades, and there is a growing body of clinical evidence supporting their efficacy in certain applications.
None of this is to suggest that essential oils should replace surgical sterilisation. That would be absurd, and no credible integrative practitioner is arguing for it. What we are arguing for is serious, well-funded research into plant-based antimicrobials as complements to — and in some contexts, alternatives to — synthetic compounds. The fact that this research remains underfunded relative to conventional pharmaceutical research is, at least in part, a consequence of where the investment incentives lie.
Lister's great insight was that you don't need to understand everything about why something works to know that it works, and to act on that knowledge. He observed, hypothesised, tested, and measured. That is what we are asking mainstream medicine to do with the plant kingdom's antimicrobial toolkit — most of which they don't want you to know about, because it's difficult to patent a plant.
Conclusion: What Lister Would Have Thought
We cannot know what Lister would make of the modern hospital. But we can read what he wrote and draw inferences. He was a man of deep faith — a Quaker who saw in the natural world evidence of a divine order that medicine should work with, not against. He was a meticulous scientist who would have been appalled at research that lacked rigour. And he was, above all, a clinician whose north star was patient outcomes.
If plant-based antimicrobials can be shown to work — by the same standards of rigorous clinical evidence that Lister applied to carbolic acid — then Lister's legacy demands that we take them seriously. If the answer turns out to be that some work and some don't, that is exactly what good science should reveal. What is not consistent with Lister's legacy is dismissing the entire inquiry because the compounds in question cannot be patented and sold at scale by a multinational chemical company.
The lesson Lister taught us was simple: look at what nature is telling you, test it rigorously, and act on the evidence. We should apply that lesson to the whole of medicine — not just the parts that are profitable.